Scinai Immunotherapeutics Reports 300% Surge in CDMO Orders and $5.3 Million Financing, Extending Cash Runway into 2027

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) disclosed a sharp expansion in its contract development and manufacturing organization (CDMO) business alongside strengthened liquidity, according to a shareholder letter from CEO Amir Reichman. The company reported approximately $8.1 million in committed customer orders as of Oct. 20, 2026, up more than 300% from $1.9 million at year-end 2025. That growth was anchored by a new agreement with a U.S.-based biopharmaceutical company that includes roughly $5.1 million in committed base service fees. The same agreement contemplates approximately $5.85 million in additional, uncommitted services, lifting the combined potential opportunity above $10 million, subject to further agreements and project milestones. For readers tracking the biopharma services sector, the figures suggest Scinai is converting its Jerusalem and Yavne manufacturing footprint into a more meaningful revenue stream. Scinai also reported approximately $5.3 million in combined net proceeds from recent equity financings, including a standby equity purchase agreement drawdown and a private placement with warrant exercises. Management estimates that current cash resources and expected customer payments will support operations through late 2027, potentially extending into the third quarter of 2028 if additional project phases are activated and delivered. That runway guidance matters because it reduces near-term financing risk for a small-cap company and gives management room to pursue growth without immediate dilution. The company said it remains focused on expanding its CDMO customer base, improving facility utilization and pursuing capital-efficient development of its NanoAb immunotherapy platform through grants and partnerships. Scinai describes itself as a biopharmaceutical company developing innovative immunology therapies, with candidates licensed from the Max Planck Society and PinCell S.r.l., and it owns Scinai Biopharma Services Ltd., the CDMO arm serving biotechnology and pharmaceutical companies. The full press release is available at https://ibn.fm/3C1F4, and the latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI. The announcement was distributed through InvestorWire, a communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire notes that its services include editorial syndication to 5,000+ outlets and social media distribution via IBN. Terms of use and disclaimers applicable to InvestorWire content are posted at https://www.InvestorWire.com/Disclaimer.